US-based public benefit drug manufacturing corporation Phlow has received $354m funding from the government to produce essential medicines at risk of shortage amid the Covid-19 pandemic.
The contract from the Biomedical Advanced Research and Development Authority (BARDA) also covers advanced manufacturing of drugs for potential Covid-19 treatment.
Valued up to $812m, the contract involves a four-year base award of $354m and additional $458m as potential options for long-term sustainability.
Phlow is working with its partners Civica Rx, Virginia Commonwealth University’s Medicines for All Institute and AMPAC Fine Chemicals to produce chemical precursor ingredients and active pharmaceutical ingredients (APIs).